Therapy News and Research

RSS

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.

2 Jun 2012

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

2 Jun 2012

Two tumor suppressor genes function to disrupt overactive EGFR signaling

Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed resistance to these drugs and are therefore no longer responsive to drug treatment.

2 Jun 2012

Non-invasive stimulation of cerebellum helps individuals learn new walking patterns

In a step towards improving rehabilitation for patients with walking impairments, researchers from the Kennedy Krieger Institute found that non-invasive stimulation of the cerebellum, an area of the brain known to be essential in adaptive learning, helped healthy individuals learn a new walking pattern more rapidly.

2 Jun 2012

HealthSouth to build comprehensive physical rehabilitation hospital in greater Orlando

HealthSouth Corporation today announced it has received permission from the state to proceed with building a comprehensive physical rehabilitation hospital in the greater Orlando, Fla., market. The 50-bed hospital will provide comprehensive physical rehabilitation to patients who have experienced stroke, trauma, brain and orthopedic injuries or other major illness or injuries.

2 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research.

2 Jun 2012

UH CNRCS students achieve significant milestones in cancer therapy research

Four University of Houston (UH) students are well on their way to emerging cancer research careers upon achieving significant milestones this spring in their work toward new therapies for prostate and breast cancer.

2 Jun 2012

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

BSD Medical Corporation, a developer and manufacturer of advanced medical systems that utilize heat therapy to treat cancer, announced today that a distinguished, international team of leading oncologists met in council while attending the May 2012 conference of the European Society for Radiotherapy and Oncology (ESTRO) in Barcelona, Spain.

2 Jun 2012

Exercise reduces expression of cytokines and alleviates neuropathic pain

Exercise helps to alleviate pain related to nerve damage (neuropathic pain) by reducing levels of certain inflammation-promoting factors, suggests an experimental study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jun 2012

New medication proves effective in slowing the spread of metastatic prostate cancer

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

2 Jun 2012

HIV markets in rich, poor countries are two distinct markets

HIV drugs have not only "transformed a fatal disease into a chronic one," but "[t]hey have also made HIV a big business," this Economist editorial states.

2 Jun 2012

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

2 Jun 2012

New $25M HHS funding to support Aging and Disability Resource Centers in all states

Health and Human Services (HHS) Secretary Kathleen Sebelius today announced a new $25 million funding opportunity made possible by the Affordable Care Act to help states strengthen and expand their ability to help seniors and people with disabilities access home and community-based long-term services and supports. Over the next one to three years, funding will support Aging and Disability Resource Centers (ADRCs) in nearly every state.

2 Jun 2012

Study provides novel mechanism of action of anti-cancer compound: perifosine

Aeterna Zentaris Inc. today announced that an article published in the May 2012 issue of Plos One, outlines a novel mechanism of action of the Company's oral anti-cancer compound, perifosine, which could provide a rationale for a novel approach to the treatment of Malignant Pleural Mesothelioma (MMe), an aggressive type of cancer associated with exposure to asbestos.

2 Jun 2012

America's biopharmaceutical researchers work on many new approaches to fight cancer

America's biopharmaceutical research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients worldwide, according to a report released today by the Pharmaceutical Research and Manufacturers of America.

2 Jun 2012

Study identifies several proteins as new therapeutic targets and biomarkers for kidney cancer

Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.

2 Jun 2012

First U.S.-based study to assess per-patient annual economic costs of fecal incontinence

Care for patients with fecal incontinence costs $4,110 per person for both medical and non-medical costs like loss of productivity, according to new research from the University of Michigan.

2 Jun 2012

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers.

2 Jun 2012

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.

2 Jun 2012

Therapy News and Research

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Two tumor suppressor genes function to disrupt overactive EGFR signaling

Non-invasive stimulation of cerebellum helps individuals learn new walking patterns

HealthSouth to build comprehensive physical rehabilitation hospital in greater Orlando

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

UH CNRCS students achieve significant milestones in cancer therapy research

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

Exercise reduces expression of cytokines and alleviates neuropathic pain

New medication proves effective in slowing the spread of metastatic prostate cancer

HIV markets in rich, poor countries are two distinct markets

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

New $25M HHS funding to support Aging and Disability Resource Centers in all states

Study provides novel mechanism of action of anti-cancer compound: perifosine

America's biopharmaceutical researchers work on many new approaches to fight cancer

Study identifies several proteins as new therapeutic targets and biomarkers for kidney cancer

First U.S.-based study to assess per-patient annual economic costs of fecal incontinence

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Lilly, Kowa announce results from PREVAIL U.S. study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News